123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer

Jolanta M. Durski, Carrie B. Hruska, Trond V. Bogsrud, Mabel Ryder, Geoffrey B. Johnson

Research output: Contribution to journalArticlepeer-review

Abstract

ABSTRACT: A previously published model (Atkins) allows for calculation of 131I maximum tolerated activity on the basis of 48-hour whole-body retention of 131I on a pretherapy diagnostic scan. Our practice uses iodine 123I for diagnostic imaging of metastatic thyroid cancer for staging before 131I therapy, with images typically acquired 24 hours after administration of the radiopharmaceutical. We explored the feasibility of an additional 123I whole-body scan and retention measurement at 48 hours, with application of the model to estimate maximum tolerated activity of radioiodine before 131I treatment of metastatic thyroid cancer.

Original languageEnglish (US)
Pages (from-to)e151-e153
JournalClinical nuclear medicine
Volume46
Issue number3
DOIs
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer'. Together they form a unique fingerprint.

Cite this